Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia by Yang Jun J, Cheng Cheng, Devidas Meenakshi, Cao Xueyuan, Fan Yiping, Campana Dario, Yang Wenjian, Neale Geoff, Cox Nancy J, Scheet Paul, Borowitz Michael J, Winick Naomi J, Martin Paul L, Willman Cheryl L, Bowman W Paul, Camitta Bruce M, Carroll Andrew, Reaman Gregory H, Carroll William L, Loh Mignon, Hunger Stephen P, Pui Ching-Hon, Evans William E, Relling Mary V in Nature genetics (2011).

[PMID: 21297632] PubMed


Although five-year survival rates for childhood acute lymphoblastic leukemia (ALL) are now over 80% in most industrialized countries, not all children have benefited equally from this progress. Ethnic differences in survival after childhood ALL have been reported in many clinical studies, with poorer survival observed among African Americans or those with Hispanic ethnicity when compared with European Americans or Asians. The causes of ethnic differences remain uncertain, although both genetic and non-genetic factors are likely important. Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL, we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse (P = 0.0029) even after adjusting for known prognostic factors (P = 0.017). Ancestry-related differences in relapse risk were abrogated by the addition of a single extra phase of chemotherapy, indicating that modifications to therapy can mitigate the ancestry-related risk of relapse.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.